Xeris Biopharma Holdings, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Company eliminated $33.5M in debt by converting it to stock, reducing future interest payments and financial risk.
Adding experienced biotech executive with gene therapy and clinical development expertise strengthens board oversight.
Converting debt to equity reduces interest obligations and improves the company's balance sheet health.
Stockholder votes confirm board leadership and ensure independent financial oversight of the company.
Quarterly earnings reports show investors how the company performed and whether it is growing.
Quarterly announcements let investors know company progress on sales, expenses, and strategic goals.
Board member departures can affect oversight and decision-making until a replacement is found.
Stocky reads Xeris Biopharma Holdings, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Xeris Biopharma Holdings, Inc.'s most recent tracked filing was a 8-K on 17 Jul 2026: Completed debt-to-equity exchange eliminating all convertible notes.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.